{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"0.70"},{"groupId":"OG001","spread":"0.21","value":"0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"-0.01"},{"groupId":"OG001","spread":"0.22","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Day 1: Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.22","value":"0.02"},{"groupId":"OG001","spread":"0.20","value":"-0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Day 1: Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"-0.03"},{"groupId":"OG001","spread":"0.15","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"Day 1: Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.19","value":"-0.02"},{"groupId":"OG001","spread":"0.23","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Day 1: Cycle 17"}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health and wellbeing. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale (for the 5L version). The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on safety population evaluable for health state utility index. Here, 'Number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle (Cycle 3, Cycle 6, Cycle 9, and Cycle 17)","title":"Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health State Utility Index Value","type":"SECONDARY","unitOfMeasure":"score on a scale"}